Compounds that block Aβ binding to PrPC, or that inhibit activation of downstream signaling mechanisms, have been shown to ameliorate pathology in AD transgenic models31,32, and some of these are being tested in human patients33. The gene discussed is PRNP; the disease is Alzheimer disease.